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Summary
QUESTIONS UNDER STUDY / PRINCIPLES: The main
aim of this study was to investigate profiles of drug users,
with a particular focus on illicit drugs other than cannabis,
and to explore the effect of early-onset intensive use
(drunkenness, daily smoking, high on cannabis) on profiles
of illicit drug use.
METHODS: Baseline data from a representative sample of
5,831 young Swiss men in the ongoing Cohort Study on
Substance Use Risk Factors were used. Substance use (al-
cohol, tobacco, cannabis and 15 types of other illicit drug)
and age of onset of intensive use were assessed. The Item
Response Theory (IRT) and prevalence rates at different
ages of onset were used to reveal different profiles of illicit
drug use.
RESULTS: In addition to cannabis, there were two profiles
of other illicit drug use: (a) “softer” drug users (uppers,
hallucinogens and inhaled drugs), among which ecstasy
had the highest discriminatory potential (IRT slope = 4.68,
standard error (SE) = 0.48; p <0.001); and (b) “harder”
drug users (heroin, ketamine, gamma-hydroxybutyrate/
gamma-hydroxylactone, research chemicals, crystal meth
and spice), among which ketamine had the highest discrim-
inatory potential (slope = 4.05; SE = 0.63; p <0.001). Onset
of intensive use at the age of 12 years or younger also dis-
criminated between these two profiles.
CONCLUSION: Both the IRT model and the effect of on-
set of intensive use enabled two groups of illicit drugs to
be identified. In particular, very early onset (at 12 years or
younger) intensive use of any substance was a marker for
later use of the second group of drugs.
Keywords: drug use; early onset; intensive use; profiles of
drug users
Introduction
The stages of involvement in drug use are commonly
agreed upon [1–5]. The sequence goes from the use of licit
drugs (alcohol and tobacco) to cannabis use, and then the
use of other illicit drugs [6–13]. However, although there
are many studies on the pathway from licit drug use to
cannabis use, and finally to other illicit drugs, there is not
much detailed information about the potential stages of the
use of illicit drugs other than cannabis. Researchers mostly
refer to “hard drug use” [1, 14, 15] and aggregate all illicit
drugs apart from cannabis into a single class [2], without
providing any information on their potential sequential use.
Occasionally, studies have reported that heroin use is the fi-
nal stage of the sequence [8, 16, 17]. The use of cocaine,
gamma-hydroxybutyrate/gamma-hydroxylactone (GHB/
GBL) and ketamine is more common among people with
extensive drug histories and seems to occur late in the se-
quence of illicit drug use [18]. The most common order ap-
pears to be cannabis, pills, cocaine and then heroin [7], but
this order is sometimes described as unstable [19, 20]. The
present study provides insight into the profiles of the users
of illicit drugs other than cannabis. With a large sample
size, differences between 15 types of illicit drug besides
cannabis were analysed.
The literature also shows that early use of cannabis or al-
cohol is an important predictor of drug-use trajectories [7,
21–24]. Early alcohol, tobacco and cannabis use are three
of the most relevant factors influencing use of other illi-
cit drugs [16]. Studies have tended to look at early-onset
use generally, rather than at whether intensive early-on-
set use (of alcohol, tobacco or cannabis) is associated with
later use of illicit drugs other than cannabis. However, early
drunkenness poses a greater risk of behavioural problems
among adolescents than simple early onset of alcohol use
[22].
The present study had two objectives. The principal aim
was to identify the profiles of users of the most common
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 1 of 13
drugs. We use “profiles of drug users” instead of “stages
of drug use” because of the cross-sectional design of the
study. However, even cross-sectional studies enable ex-
amination of sequential phenomenon [25]. The gateway
theory has been studied from two perspectives: temporal
sequences of drug use [26], and the strength of the associ-
ation between drugs [25, 27, 28] as used in this study. The
study also explored the effect of intensive early-onset use
of alcohol, tobacco and cannabis on the likelihood of initi-
ating other illicit drug use, that is, the effect of the first ex-
perience of being drunk or of being high on cannabis. We
also investigated the age of onset of intensive tobacco use
(i.e. daily smoking); smoking is less frequently described
as a gateway drug, but this study aimed to provide fur-
ther information on its effect. An additional aim was to
provide data on the prevalence of drug use among young
Swiss men; indeed, data on drug use are scarce in Switzer-
land, where no detailed information comparable to that
provided by studies in various other European coutries is
available (see for example the European Monitoring Centre
for Drugs and Drug Addiction [EMCDDA] studies in the
European Union, e.g. http://www.emcdda.europa.eu).
Methods
The data used in this study were derived from the Cohort
Study on Substance Use Risk Factors (C-SURF), a lon-
gitudinal study designed to assess substance use patterns
and related consequences in young Swiss men. The pro-
tocol (Protocol No. 15/07) was approved by the Ethics
Committee for Clinical Research of Lausanne University
Medical School. Participants were selected at three of six
army recruitment centres, in Lausanne (French-speaking)
and Windisch and Mels (German-speaking), between
August 23, 2010 and November 15, 2011. These three
centres cover 21 of the 26 cantons in Switzerland, includ-
ing all French-speaking cantons. The recruitment centres
cover the smaller inner Cantons of Switzerland in the rural
region of the Alps, but also large Swiss cities (Basel for
the German-speaking region, Geneva and Lausanne for the
Francophone region and Bern for the bilingual area). The
German-speaking centres were suggested by the army ad-
ministration because they were the biggest centres with the
highest number of people going through the recruitment
process. We avoided the Ceneri (the centre for Italophone
men), mainly for organisational reasons and to avoid run-
ning a study in three different languages (Italophones rep-
resent less than 5% of the Swiss population). Thus, the
study is largely representative of all Swiss men, although
the upper North of Switzerland and particularly the Zurich
region was not represented. Army recruitment is mandatory
in Switzerland; therefore, all young men around 20 years
old were eligible for study inclusion. Briefly, of the 13,245
conscripts informed about the study, 7,563 (57.1%) gave
written consent to participate and 5,990 (79.2%) of these
Figure 1
Criterion information curves for drug use.
The criterion information curves represent how each criterion
measured the underlying latent trait. The point on the x-axis where
the probability of endorsement (y-axis) is 50% determined the
severity parameter. The discrimination parameter of each criterion
is the slope: the steeper slopes had higher discrimination
parameters. Thus, ecstasy and ketamine discriminate very strongly
between different drug users (high values on the y-axis), whereby
ecstasy is less severe (more left = 1.59) compared with ketamine
(more to the right with severity = 2.23) as regards the latent trait
(substance use severity). (Detailed values can be found in table 4.)
Table 1: Participants’ characteristics.
Sociodemographic variables
Age (years) mean (standard deviation) 20.0 (1.24)
Language
French-speaking 55.4%
German-speaking 44.6%
Civil status
Single 94.9%
Living with a partner 4.4%
Maried 0.4%
Education
Primary (9 years) 48.2%
Secondary (12 years) 26.2%
Tertiary and higher (>13 years) 25.6%
Family income
Below average 14.5%
Average 41.4%
Above average 44.1%
Residence
Urban 41.4%
Rural 58.6%
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filled out the baseline questionnaire. More details about
sampling and nonresponse are provided in Studer et al.
[29]. Briefly, nonrespondents were more likely to be sub-
stance users and used substances more frequently. In gen-
eral, however, differences between respondents and non-
respondents were small and probably only significant be-
cause of the large sample size. Missing values among par-
ticipants were listwise deleted, so the study ultimately in-
cluded 5,831 participants (97.4% of the sample).
Illicit drug use
Fifteen questions measured lifetime use of illicit drugs;
answers were coded as “used” or “nonused”. The sub-
stances were as follows: (1.) hallucinogens, magic mush-
rooms, psylocibin, peyote, mescalin; (2.) other hallucino-
gens (lysergide [LSD], phencyclidine [PCP, Angel Dust],
4-bromo-2,5-dimethoxyphenethylamine [2C-B],
2,5-dimethoxy-4-iodophenethylamine [2C-I]); (3.) Salvia
divinorum; (4.) speed; (5.) amphetamine, metamphetamine,
amphetaminsulfate (e.g. Dexedrine, Benzedrine); (6.) crys-
tal meth (ice); (7.) poppers (amylnitrite, butylnitrite); (8.)
solvent sniffing (e.g. glue, solvent and gases such as ben-
zine, ether, toluol, trichloroethylene, nitrous oxide); (9.)
ecstasy, 3,4-methylenedioxy-N-methylamphetamine
(MDMA); (10.) cocaine, crack, freebase; (11.) heroin; (12.)
ketamine (Special K), dextromethorphan (DXM); (13.)
GHB / GBL / I-4 Butandiol (BDB); (14.) research chemic-
als (e.g. mephedrone, butylone and methedrone); and (15.)
spices or similar substances. Use of these drugs over the
previous 12 months was also assessed.
Cannabis use
Cannabis use was assessed by asking participants if they
had ever smoked cannabis (hashish, marijuana or grass) be-
fore; the study will refer to cannabis, the most common
term, but the principal psychoactive constituent of cannabis
is delta-9-tetrahydrocannabinol (THC). Answers were
coded as “used” or “nonused”. They were also asked at
what age they had got high on cannabis for the first time.
Figure 2
Prevalence rates of drug use according to age of first getting high
with cannabis.
The prevalence rate for each drug is given according to the age of
first getting high with cannabis. For example, 14.9% of the
participants who first got high with cannabis at age 12 years or
earlier used heroin, whereas only 2.4% of the participants who first
got high with cannabis at age 13 to 15 used heroin (percentages
can be found in table 5).
Lifetime use was assessed instead of previous 12-month
use, because the aim was to analyse the effects of early on-
set of cannabis use on stages of other lifetime drug use, and
not only current consumption. The relevant age of onset of
intensive use (first time high) was selected as follows: “age
12 years or earlier”, “age 13 to 15 years”, “age 16 to 18
years”, “age 19 years or older” and “never” (noncannabis
users and participants who had never got high with can-
nabis). Previous studies reported that those who first used
cannabis before the age of 12 were twice as likely to have
severe mental illness (SMI) as those who first used can-
nabis at the age of 18 or older ([30], see p. 69 for SMI
definition). Early cannabis use (before the age of 16) pre-
dicted later dependence [31], and cannabis use at the age of
18 or younger predicted impairment and irreversible harm
[32]. These categories were selected to test the effect of
early intensive use rather than early initiation.
Tobacco use
Participants were asked if they had ever smoked. They
were recorded as users if they had smoked at least 50 ci-
garettes, or 10 water pipes, or 25 cigars or cigarillos, or
25 pipes. Twelve-month use was similarly assessed. Age of
onset of intensive use was assessed using the age at which
participants started to smoke daily. The same age categor-
ies as those for cannabis were used.
Alcohol use
Alcohol use was assessed by asking participants if they had
had a total of at least 12 drinks of any kind of alcohol
in their entire life. Answers were coded as “used” or “no-
nused”, and 12-month use was also assessed. Participants
were asked how old they were when they got drunk for
the first time. The same age categories as those described
above were used.
Statistical analysis
The item-response theory (IRT) was used to define profiles
of drug users. The IRT is a latent trait theory, which sup-
poses that an item is a function of an unobservable or
latent trait. It assumes that each item does not have the
same level of severity, unlike Likert scaling, which as-
sumes that the different items are equivalent. The IRT or-
ders the items according to their severity level across the
underlying trait [33]. Different IRT models can be used.
We selected the two-parameter logistic model [34, 35] after
checking the unidimensionality of the construct (a pre-
requisite for IRT) with an exploratory factorial analysis for
ordinal data (WLSMV: weighted least squares means and
variance adjusted estimation). This model defines the re-
lationship between the observed data and an underlying
latent construct with two parameters: a severity parameter
(threshold) and a discrimination parameter (slope). The
severity parameter reveals whether each criterion (each
drug in the current study) is endorsed less frequently, for
example, is more “severely” reported. This parameter is the
point of the latent construct where there is 50% endorse-
ment. The discrimination parameter is represented by the
steepness of the slope and shows the ability of a criterion
to discriminate between participants who are low or high
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on the latent construct. These two parameters were plotted
graphically on a “criterion information curve.”
Proportion tests (z-tests) were used to explore the effect of
the age of onset of intensive use of alcohol, tobacco or can-
nabis on illicit drug use. Comparisons were made between
the proportions of users of each drug who initiated intens-
ive use at 16 to 18 years of age and those who initiated at
13 to 15 years of age. The 13 to 15 onset group was sim-
ilarly compared with the adjacent 12 years or younger on-
set group. We also ran logistic regression models separately
with each illicit drug as the outcome and onset of intens-
ive use as exposure, while controlling for the actual age
of respondents. However, as age at conscription was very
homogeneous, we did not report these models separately.
Differences between models adjusted for age and models
without adjustment were negligible as expected, and did
not result in any different findings.
Results
Prevalence of substance use
The participants’ characteristics are described in table 1.
The prevalence rates of substance use are given in table
2. Only 4.2% of participants did not use any drugs, and
the most prevalent drugs were licit drugs. Alcohol was the
most prevalent (95.8% for lifetime use), followed by to-
bacco (94.8%), then cannabis (47.6%), and finally the oth-
er illicit drugs. Hallucinogens (magic mushrooms 5.7%,
other hallucinogens 4.2%, Salvia divinorum 5.2%), uppers
(speed 4.7%, ecstasy 5.7%, cocaine 5.5%, amphetamines/
methamphetamines 3.4%) and inhaled drugs (poppers
5.2%, solvents, 4.8%) had a prevalence of approximately
4% to 5% (except for amphetamines and methamphetam-
ines). The remaining illicit drugs (ketamine, heroin, GHB/
GBL, research chemicals such as mephedrone or butylon,
crystal meth and spice) had a lower prevalence of approx-
imately 1%.
Table 3 illustrates the percentages of respondents broken
down by age of first drunkenness, first daily smoking and
first time being high on cannabis. Between 13 and 18 years
of age, a total of 36.2% of participants had got high on can-
nabis, 28% had smoked daily, and 81.7% had got drunk for
the first time. Late or early intensive use was less preval-
ent. Intensive alcohol use was more prevalent than intens-
ive cannabis use, and intensive tobacco use was the least
prevalent.
IRT model parameters and criterion information
curves
The unidimensionality of the data was first checked with
an exploratory factorial analysis. The first factor explained
71.04% of the variance. The IRT model parameters and
associated criterion information curves for each drug are
shown in table 4 and figure 1. Severity was lowest for al-
cohol, tobacco and cannabis, and greatest for spice, ketam-
ine, GHB/GBL, crystal meth, research chemicals, heroin,
solvent sniffing and poppers. The other drugs were inter-
mediate in terms of severity. Discrimination was low for
alcohol, tobacco, cannabis and inhaled drugs (poppers and
solvents), and high for ecstasy and ketamine.
Table 2: Lifetime use and use in the previous 12 months.
Percentage users (n = 5,831)
Lifetime Previous 12 months
Total (at least one drug used) 95.8 (n = 5,586) 94.2 (n = 5,493)
Alcohol 94.8 92.9
Tobacco 60.4 45.7
Cannabis 47.6 30.7
Hallucinogens / magic mushrooms 5.7 2.8
Ecstasy 5.7 3.7
Cocaine 5.5 3.2
Salvia divinorum 5.2 2.2
Poppers 5.2 2.4
Solvent sniffing 4.8 2.2
Speed 4.7 2.6
Other hallucinogens 4.2 2.3
Amphetamine/methamphetamine 3.4 2.0
Spice 1.4 0.5
Ketamine 1.3 0.6
GHB/GBL 1.2 0.5
Crystal meth 1.1 0.4
Research chemicals 1.1 0.5
Heroin 1.0 0.4
GBH = gamma-hydroxybutyrate; GBL = gamma-hydroxylactone
Table 3: Intensive use onset: percentage of participants by age categories.
Nonusers / No
intensive onset
≥19 years 16–18 years 13–15 years ≤12 years
High on cannabis 59.9 2.2 22.2 14.0 1.7
Daily smoking 68.4 2.8 20.0 8.0 0.7
Drunkenness 12.6 3.4 38.7 43.0 2.3
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Comparison of drug users by age of onset of intensive
use
The results of the proportion comparisons are summarised
in tables 5, 6 and 7; figures 2, 3 and 4 give an overview of
the prevalence rates for different ages of onset of intensive
use. The higher the number of participants who got high
on cannabis at an early age, the greater the increase in the
proportion of users of each drug within the age classes of
onset of intensive use of cannabis (table 5). For example,
33.7% of those who got high at the age of 12 or earlier
also used cocaine, whereas only 20.7% of those who got
high between 13 and 15 did so. The proportions began to
increase at age 13 to 15 for most of the drugs (hallucino-
gens and uppers, as described in the previous section), but
only at an onset of intensive cannabis use at 12 or earlier
for ketamine, GHB/GBL, heroin, research chemicals, crys-
tal meth and spice (fig. 2). There were no statistical differ-
ences in proportions between cannabis use onset at 16 to 18
compared with 13 to 15 for these drugs.
The patterns were quite similar for onset of intensive use
of alcohol (table 6, fig. 3), with a commonly observed
steep increase from 13 to 15 to 16 to 18 for first drunk-
enness. The effects were only significant as a tendency (p
<0.10) for solvents (comparison of age 16–18 and 13–15),
GHB/GBL and heroin (comparison of age 13–15 and 12
and younger). The differences between 13 to15 and 12 and
younger for ketamine, research chemicals, crystal meth and
spice were smaller for onset of intensive alcohol use than
for onset of intensive cannabis use.
Finally, for the age of onset of intensive tobacco use, the
results showed similar tendencies, except for solvents, for
which proportions did not differ between the 16 to18 and
13 to 15 age groups (table 7). Salvia divinorum and poppers
showed differences only at borderline significance levels (p
<0.10) between 16 to 18 and 13 to 15. The patterns were a
little less clear than for onset of intensive cannabis and al-
cohol use (see fig. 5), but the prevalence for very early on-
set of daily smoking was similar to that for cannabis onset
and inferior to that for early alcohol onset.
Discussion
Principal findings and implications
The results of the IRT model were in accordance with the
results of previous studies: the profiles of drug users went
from licit drug users (first alcohol users, then alcohol and
tobacco users), to cannabis users and then to users of harder
illicit drugs. However, there was not one but two profiles
for the other illicit drug users. Hallucinogens such as magic
mushrooms, LSD and Salvia divinorum, uppers like speed,
ecstasy, cocaine, amphetamines and methamphetamines,
and inhaled drugs (known as recreational drugs) such as
poppers or solvents constituted the first profile of other il-
licit drug users, with ecstasy having the strongest discrim-
inatory potential. A second profile was formed for the oth-
er users of other “hard” drugs, like ketamine, heroin, GHB/
GBL, research chemicals, crystal meth and spice. The res-
ults showed that use of these drugs was less prevalent
among participants, and that their severity parameters were
Figure 3
Prevalence rates for drug use according to age at first
drunkenness.The prevalence rate for each drug is given according
to the age of onset of being drunk. For example, 7.0% of the
participants who first got drunk at age 12 years or earlier used
heroin, whereas only 1.3% of the participants who first got drunk at
age 13 to 15 used heroin (percentages can be found in table 6).
Table 4: Criterion response model parameters.
Severity = threshold Discrimination = slope
Alcohol –3.35 (0.06)*** 0.59 (0.00)
Tobacco –0.32 (0.02)*** 1.39 (0.08)***
Cannabis 0.08 (0.02)*** 1.41 (0.08)***
Hallucinogens / magic mushrooms 1.78 (0.05)*** 1.93 (0.12)***
Ecstasy 1.59 (0.03)*** 4.68 (0.48)***
Cocaine 1.68 (0.04)*** 2.95 (0.22)***
Salvia divinorum 1.93 (0.05)*** 1.62 (0.09)***
Poppers 2.22 (0.08)*** 1.13 (0.07)***
Solvent sniffing 2.49 (0.11)*** 0.94 (0.06)***
Speed 1.72 (0.04)*** 3.38 (0.30)***
Other hallucinogens 1.76 (0.04)*** 3.63 (0.36)***
Amphetamine/methamphetamine 1.85 (0.04)*** 3.55 (0.35)***
Spice 2.46 (0.09)*** 1.99 (0.20)***
Ketamine 2.23 (0.06)*** 4.05 (0.63)***
GHB/GBL 2.36 (0.08)*** 2.85 (0.34)***
Crystal meth 2.43 (0.09)*** 2.52 (0.28)***
Research chemicals 2.42 (0.09)*** 2.64 (0.38)***
Heroin 2.42 (0.08)*** 2.86 (0.39)***
Standard errors are given in parentheses. *** p <0.001; GBH = gamma-hydroxybutyrate; GBL = gamma-hydroxylactone
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higher than for the earlier drugs in the IRT model. Thus,
the profiles of drug users included a distinction between
“soft” illicit drug users and “hard” illicit drug users. In-
terestingly, cocaine resembled a “soft drug”, despite com-
monly being regarded as a “hard drug” in terms of potential
for dependence or harm. These results may indicate differ-
ent stages of drug use, from middle-stage drugs to final-
stage drugs, which come later, as the prevalence rates sug-
gested. However, this result needs to be tested in a study of
longitudinal design, or using data on self-reported onset for
each drug [25].
The results of the proportion comparisons showed the im-
portance of an early age of onset of intensive use of can-
nabis, tobacco and alcohol in predicting an increased risk
of drug use. The earlier the age of onset of intensive use
of these drugs, the greater the risk of going on to use other
illicit drugs. A difference was identified between drugs in
the “soft” drug users profile (hallucinogens: magic mush-
rooms, other hallucinogens, Salvia divinorum; uppers: ec-
Figure 4
Prevalence rate of drug use according to age at first daily smoking.
The prevalence rate for each drug is given according to the age of
onset of daily smoking. For example, 25.0% of the participants who
smoked daily at age 12 years or earlier used heroin, whereas only
3.7% of the participants who smoked daily at age 13 to 15 used
heroin (percentages can be found in table 7).
stasy, cocaine, speed, amphetamines/methamphetamines;
and inhaled drugs: poppers, solvents) and those in the
“hard” drug users profile (ketamine, GHB/GBL, heroin, re-
search chemicals, crystal meth and spice). The risk of using
the “soft” drugs substantially increased when participants
first got high with cannabis, smoked daily or were drunk
at 13 to 15 years of age, while the risk of using the “hard”
drugs started to increase when participants first got high
with cannabis, smoked daily or were drunk at the age of
12 or younger. Therefore, onset of intensive use at an early
age (15 or younger) particularly increased the risk of us-
ing “soft” drugs, whereas onset of intensive use at a very
early age (12 or younger) particularly increased the risk
of using “hard” drugs. We identified two groups of illicit
drugs, one where the prevalence rate increased with an on-
set at age 15 or younger and one with an onset of 12 or
younger, as we found these two groups of illicit drugs in
the IRT model. This pattern was more evident for onset of
intensive use of cannabis, and less clear for onset of in-
tensive use of tobacco and alcohol. Cannabis seemed to
be a more important precursor for other drug use (heroin,
ketamine, GHB/GBL, crystal meth, research chemicals and
spice) than these two other licit drugs. Similar conclusions
regarding alcohol were also reached by Golub and Johnson
[36] in the United States.
Daily smoking onset showed a less clear picture than can-
nabis. However, very early onset of daily smoking (at 12
years of age or younger) resulted in a high prevalence of
drug use similar that of to cannabis, and a higher prevalen-
ce rate than alcohol use. Tobacco is described as a gateway
drug less frequently than alcohol and cannabis [22–24], but
it appears that very early onset of daily smoking may be as
predictive for later illicit drug use as very early cannabis
onset. Smoking nowadays is likely to be regarded as devi-
ant behaviour or predictive of later deviant behaviours such
as cannabis use, particularly at young ages [37, 38], where-
as alcohol use is a more accepted norm [39, 40]. In general,
however, very early onset of any of these three substances
Table 5: Proportion of users of each drug within age categories of onset of intensive use of cannabis.
First cannabis high z-tests
Nonuser
n = 3,484
≥19
n = 129
16–18
n = 1,299
13–15
n = 819
≤12
n = 100
16–18/
13–15
13–15/
≤12
Hallucinogens / magic mushrooms 0.009 0.047 0.071 0.207 0.337 –5.189*** –3.822***
Ecstasy 0.009 0.031 0.069 0.211 0.366 –5.427*** –4.507***
Cocaine 0.008 0.031 0.069 0.207 0.337 –5.198*** –3.759***
Salvia divinorum 0.020 0.039 0.064 0.182 0.347 –4.495*** –4.687***
Poppers 0.025 0.070 0.080 0.120 0.188 –1.650* –2.337***
Solvent sniffing 0.007 0.062 0.060 0.099 0.257 –1.713* –5.004***
Speed 0.007 0.047 0.052 0.172 0.317 –4.537*** –4.006***
Other hallucinogens 0.007 0.016 0.050 0.143 0.327 –3.523*** –4.910***
Amphetamine/methamphetamine 0.006 0.023 0.037 0.118 0.267 –3.057** –3.839***
Spice 0.005 0.008 0.009 0.036 0.168 –1.171 –2.862**
Ketamine 0.005 0.008 0.011 0.032 0.168 –0.889 –2.850**
GHB/GBL 0.005 0.008 0.008 0.032 0.119 –1.003 –1.947*
Crystal meth 0.005 0.008 0.007 0.028 0.158 –0.923 –2.638**
Research chemicals 0.006 0.008 0.005 0.029 0.109 –1.055 –1.808*
Heroin 0.005 0.008 0.005 0.024 0.149 –0.873 –2.498**
Z-tests for difference in use proportions between age 16–18 and 13–15, and between 13–15 and 12 or younger. Example of proportions: 0.366 for ecstasy means that 36.6
of those respondents who started getting high on cannabis at age 12 or younger also used ecstasy at least once in their lives.
*** p <0.001, ** p0< .01, * p <0.05, # p <0.10
GBH = gamma-hydroxybutyrate; GBL = gamma-hydroxylactone
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was associated with use of even the less common, “soft”
drugs. This may mean that early onset of intensive use of
any drug is an expression of a common general liability, a
general syndrome of deviance or a problematic behaviour-
al syndrome [41, 42], rather than an expression of a caus-
al drug use sequence in terms of gateway drugs. However,
any early intense substance use should be taken as a clear
warning sign and marker of the need for early treatment
and intervention.
The third aim of the study was to provide data on the
prevalence rates of drug use in Switzerland. The results
showed that cannabis was the most prevalent illicit drug,
with 47.6% of this sample of young men being lifetime
users. In the European Union, the lifetime prevalence rate
of cannabis use is around 32% (2.9%‒45.5%) for ages 15
to 34 [43]. However, men use cannabis more often than
woman and the present sample was composed exclusively
of men. Hallucinogens (magic mushrooms, other hallu-
cinogens, Salvia divinorum) and uppers (ecstasy, cocaine,
speed, amphetamines/methamphetamines) had a prevalen-
ce rate between 3.4% and 5.7%. The prevalence rate of
amphetamines, ecstasy and cocaine was congruent with
European results (5% [0.1–14.3], 5.5% [0.6–12.7] and
5.9% [0.1–13.6], respectively). Cocaine is the second most
experimented-with drug after cannabis in the Europe Union
(EMCDDA, 2011). Some other more uncommon drugs
such as Salvia divinorum and spice, which often have a
high media profile, still have a relatively low prevalence in
Switzerland.
Strengths and limitations
The likelihood of drug use depends on several factors, in-
cluding family structure, peer influence, availability, school
factors, neighbourhood, social norms, personality and in-
teractions between biological, psychological and social
factors [44, 45]. In other words, the stages of drug use and
the profiles of drug users depend on context and culture
[46], as well as the frequency of use of each drug. For ex-
ample, cocaine was easily available in Switzerland when
the study took place and could be described as a “fash-
ionable” drug. In contrast, heroin was less available and
more expensive in 2011 than now (e.g. ht-
tp://www.bag.admin.ch).
This investigation was the baseline study of C-SURF and
had a cross-sectional design. The order of drug use was in-
ferred on the basis of analyses that reflected hierarchical
use and the effect of early intensive use of cannabis or alco-
hol. The profiles were inferred mainly from use prevalence
because age of onset was not recorded for all drugs. To ex-
tend this result from profiles (cross-sectional perspective)
to stages (longitudinal perspective), longitudinal designs
are needed in order to verify the hypothesis of an escalation
from “soft” illicit drugs to “hard” illicit drugs. C-SURF is
a longitudinal study, and follow-up studies will aim to an-
swer this question. However, cross-sectional data give re-
liable results, for example with multistate models [25, 47],
but age reports are needed (age of onset of each drug).
Another limitation was that the profiles of drug users iden-
tified may be “typical,” being valid for most of the “oc-
casional” or “experimental” drug users [48] (90%–95% of
users) [49]. Indeed, the prevalence rates were quite low for
illicit drugs other than cannabis. However, these profiles
are not universal [7] and may differ among serious drug
users who can have an “atypical” profile. For example, ser-
ious drug users are more likely to use other illicit drugs
before cannabis [48], and alcohol is not a prerequisite for
cannabis use among them [36]. This population needs a
particular focus. It is also important to explore the effect
of light and heavy use of a drug (experimentation, regu-
lar use, abuse), whereas this study focused on the progres-
sion between different drugs. Another shortcoming is that
no women could be included. The study is largely repres-
entative of men, although it did not include the Italian-
speaking canton (Ticino), nor the upper northern region of
Switzerland (including Zurich). However, Italophones rep-
resent less than 5% of the Swiss population and are simil-
ar to Francophones in most patterns of use, so we do not
expect our findings to be biased. Not including the Zurich
area, which includes the largest city in Switzerland, may
have led to the underestimation of some multisubstance use
patterns and trajectories. However, the study included four
of the five biggest cities in Switzerland and therefore, the
omission of the Zurich area may have only marginally af-
fected the findings of the study.
Conclusions
This study provides insight into the profiles of drug users,
particularly regarding less common illicit drugs. The pro-
files differentiated between licit drug use (alcohol and then
tobacco), cannabis, and other illicit drugs such as hallu-
cinogens, uppers and inhaled drugs, and finally opiates,
crystal meth and spice. These profiles provide information
not identified in previous studies, and suggest that there
was an order in the use of other illicit drugs, in which “soft”
drugs (uppers, hallucinogens and inhaled drugs) precede
“hard” drugs (opiates, crystal meth and spice). However,
becaus of the cross-sectional study design, these results are
preliminary and the findings will be confirmed as future
data are gathered. These profiles were also seen in the early
age of onset of intensive use of cannabis, tobacco and al-
cohol: the risk of using “hard” drugs increased for those
who began intensive use of alcohol at a very early age, and
this was particularly true for cannabis. These results also
showed the ages at which interventions may be initiated to
prevent drug use. In particular, selective approaches should
be used to prevent early onset use of cannabis, tobacco and
alcohol.
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Figures (large format)
Figure 1
Criterion information curves for drug use.
The criterion information curves represent how each criterion measured the underlying latent trait. The point on the x-axis where the probability
of endorsement (y-axis) is 50% determined the severity parameter. The discrimination parameter of each criterion is the slope: the steeper
slopes had higher discrimination parameters. Thus, ecstasy and ketamine discriminate very strongly between different drug users (high values
on the y-axis), whereby ecstasy is less severe (more left = 1.59) compared with ketamine (more to the right with severity = 2.23) as regards the
latent trait (substance use severity). (Detailed values can be found in table 4.)
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Figure 2
Prevalence rates of drug use according to age of first getting high with cannabis.
The prevalence rate for each drug is given according to the age of first getting high with cannabis. For example, 14.9% of the participants who
first got high with cannabis at age 12 years or earlier used heroin, whereas only 2.4% of the participants who first got high with cannabis at age
13 to 15 used heroin (percentages can be found in table 5).
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Figure 3
Prevalence rates for drug use according to age at first drunkenness.The prevalence rate for each drug is given according to the age of onset of
being drunk. For example, 7.0% of the participants who first got drunk at age 12 years or earlier used heroin, whereas only 1.3% of the
participants who first got drunk at age 13 to 15 used heroin (percentages can be found in table 6).
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Figure 4
Prevalence rate of drug use according to age at first daily smoking.
The prevalence rate for each drug is given according to the age of onset of daily smoking. For example, 25.0% of the participants who smoked
daily at age 12 years or earlier used heroin, whereas only 3.7% of the participants who smoked daily at age 13 to 15 used heroin (percentages
can be found in table 7).
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